KR102132246B1 - 키메라 항원 수용체 및 이의 이용 방법 - Google Patents

키메라 항원 수용체 및 이의 이용 방법 Download PDF

Info

Publication number
KR102132246B1
KR102132246B1 KR1020197034038A KR20197034038A KR102132246B1 KR 102132246 B1 KR102132246 B1 KR 102132246B1 KR 1020197034038 A KR1020197034038 A KR 1020197034038A KR 20197034038 A KR20197034038 A KR 20197034038A KR 102132246 B1 KR102132246 B1 KR 102132246B1
Authority
KR
South Korea
Prior art keywords
leu
ser
val
gly
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197034038A
Other languages
English (en)
Korean (ko)
Other versions
KR20190131152A (ko
Inventor
치아-융 우
제임스 오누퍼
웬델 에이. 림
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Priority to KR1020207019131A priority Critical patent/KR102332790B1/ko
Publication of KR20190131152A publication Critical patent/KR20190131152A/ko
Application granted granted Critical
Publication of KR102132246B1 publication Critical patent/KR102132246B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A61K2239/24—Dimerizable CARs; CARs with adapter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020197034038A 2013-02-15 2014-02-14 키메라 항원 수용체 및 이의 이용 방법 Active KR102132246B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207019131A KR102332790B1 (ko) 2013-02-15 2014-02-14 키메라 항원 수용체 및 이의 이용 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361765585P 2013-02-15 2013-02-15
US61/765,585 2013-02-15
PCT/US2014/016527 WO2014127261A1 (en) 2013-02-15 2014-02-14 Chimeric antigen receptor and methods of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157024731A Division KR102064230B1 (ko) 2013-02-15 2014-02-14 키메라 항원 수용체 및 이의 이용 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207019131A Division KR102332790B1 (ko) 2013-02-15 2014-02-14 키메라 항원 수용체 및 이의 이용 방법

Publications (2)

Publication Number Publication Date
KR20190131152A KR20190131152A (ko) 2019-11-25
KR102132246B1 true KR102132246B1 (ko) 2020-07-09

Family

ID=51354582

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020197034038A Active KR102132246B1 (ko) 2013-02-15 2014-02-14 키메라 항원 수용체 및 이의 이용 방법
KR1020157024731A Active KR102064230B1 (ko) 2013-02-15 2014-02-14 키메라 항원 수용체 및 이의 이용 방법
KR1020237003986A Active KR102813881B1 (ko) 2013-02-15 2014-02-14 키메라 항원 수용체 및 이의 이용 방법
KR1020207019131A Active KR102332790B1 (ko) 2013-02-15 2014-02-14 키메라 항원 수용체 및 이의 이용 방법
KR1020217038402A Ceased KR20210147101A (ko) 2013-02-15 2014-02-14 키메라 항원 수용체 및 이의 이용 방법

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020157024731A Active KR102064230B1 (ko) 2013-02-15 2014-02-14 키메라 항원 수용체 및 이의 이용 방법
KR1020237003986A Active KR102813881B1 (ko) 2013-02-15 2014-02-14 키메라 항원 수용체 및 이의 이용 방법
KR1020207019131A Active KR102332790B1 (ko) 2013-02-15 2014-02-14 키메라 항원 수용체 및 이의 이용 방법
KR1020217038402A Ceased KR20210147101A (ko) 2013-02-15 2014-02-14 키메라 항원 수용체 및 이의 이용 방법

Country Status (20)

Country Link
US (10) US20150368342A1 (enExample)
EP (5) EP2956175B1 (enExample)
JP (5) JP6450690B2 (enExample)
KR (5) KR102132246B1 (enExample)
CN (2) CN110423282B (enExample)
AU (5) AU2014216130B2 (enExample)
CA (1) CA2901115A1 (enExample)
CY (1) CY1122386T1 (enExample)
DK (2) DK2956175T3 (enExample)
ES (3) ES2758227T3 (enExample)
HR (1) HRP20192123T1 (enExample)
HU (2) HUE036250T2 (enExample)
IL (3) IL272279B2 (enExample)
LT (2) LT2956175T (enExample)
MX (2) MX369545B (enExample)
NO (1) NO2929995T3 (enExample)
PL (3) PL2956175T3 (enExample)
PT (3) PT2956175T (enExample)
SI (2) SI3613439T1 (enExample)
WO (1) WO2014127261A1 (enExample)

Families Citing this family (332)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
KR102437522B1 (ko) * 2012-05-25 2022-08-26 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US9511092B2 (en) 2013-01-28 2016-12-06 St. Jude Children's Research Hospital, Inc. Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
SI3613439T1 (sl) 2013-02-15 2021-11-30 The Regents Of The University Of California Himerni antigenski receptor in postopki njegove uporabe
JP6541639B2 (ja) 2013-03-14 2019-07-10 ベリカム ファーマシューティカルズ， インコーポレイテッド Ｔ細胞増殖をコントロールするための方法
EP2970426B1 (en) * 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
AU2014296626B2 (en) * 2013-07-29 2019-03-07 Regeneron Pharmaceuticals, Inc. Multipartite signaling proteins and uses thereof
CA2925421C (en) 2013-09-24 2023-08-29 Medicenna Therapeutics, Inc. Interleukin-2 fusion proteins and uses thereof
SG10201809385RA (en) 2013-12-17 2018-11-29 Genentech Inc Anti-cd3 antibodies and methods of use
EP4420663A3 (en) * 2013-12-20 2024-10-30 Novartis AG Regulatable chimeric antigen receptor
EP3094354B1 (en) * 2014-01-14 2018-10-17 Cellectis Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish
US10934346B2 (en) 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
GB201405845D0 (en) * 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
CN111514283B (zh) 2014-04-07 2025-10-14 诺华股份有限公司 使用抗cd19嵌合抗原受体治疗癌症
SG11201608862SA (en) 2014-04-23 2016-11-29 Juno Therapeutics Inc Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
EP3134102B1 (en) 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
US10428305B2 (en) 2014-05-15 2019-10-01 National University Of Singapore Modified natural killer cells that express IL15 and uses thereof
ES2928000T3 (es) * 2014-06-06 2022-11-14 Memorial Sloan Kettering Cancer Center Receptores de antígeno quimérico dirigidos a mesotelina y usos de los mismos
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
MX2017001011A (es) 2014-07-21 2018-05-28 Novartis Ag Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
WO2016019300A1 (en) 2014-07-31 2016-02-04 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
US20170260261A1 (en) * 2014-08-28 2017-09-14 Bioatla, Llc Conditionally Active Chimeric Antigen Receptors for Modified T-Cells
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
GB201415347D0 (en) * 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
EP3189148A4 (en) 2014-09-02 2018-05-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
AU2015310897B2 (en) 2014-09-04 2020-03-19 Cellectis Trophoblast glycoprotein (5T4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
ES2891332T3 (es) 2014-09-17 2022-01-27 Novartis Ag Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
JP2017532325A (ja) * 2014-10-03 2017-11-02 イエール ユニバーシティ 抗癌療法のための自然免疫系の改変
RU2017115808A (ru) * 2014-10-07 2018-11-13 Селлектис Способ модуляции активности car-индуцированных иммунных клеток
US10774388B2 (en) 2014-10-08 2020-09-15 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
US10201606B2 (en) 2014-11-26 2019-02-12 Miltenyi Biotec Gmbh Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
HK1251862A1 (zh) * 2014-12-02 2019-04-26 普拉斯派克特查特凯尔Rwmc有限责任公司 治疗癌症的方法和组合物
LT3227339T (lt) 2014-12-05 2022-01-10 Memorial Sloan-Kettering Cancer Center Chimeriniai antigeno receptoriai, nukreipti į receptorių su prijungtu g baltymu ir jų naudojimo būdai
EP3227324A4 (en) 2014-12-05 2018-08-29 Memorial Sloan Kettering Cancer Center Antibodies targeting g-protein coupled receptor and methods of use
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
HK1245827B (en) * 2014-12-15 2020-06-19 Board Of Regents Of The University Of Texas System Methods for controlled activation or elimination of therapeutic cells
HRP20250129T1 (hr) 2014-12-15 2025-04-11 The Regents Of The University Of California Bispecifični or-gate kimerni antigenski receptor koji reagira na cd19 i cd20
WO2016097334A1 (en) * 2014-12-19 2016-06-23 ETH Zürich Chimeric antigen receptors and methods of use
WO2016098078A2 (en) * 2014-12-19 2016-06-23 Novartis Ag Dimerization switches and uses thereof
PL3237436T3 (pl) 2014-12-24 2020-03-31 Aadigen, Llc Peptydy i nanocząsteczki do wewnątrzkomórkowego dostarczania cząsteczek
CA3197849A1 (en) 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
GB201501936D0 (en) * 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201503133D0 (en) 2015-02-24 2015-04-08 Ucl Business Plc And Syncona Partners Llp Chimeric protein
KR102632082B1 (ko) 2015-02-27 2024-02-02 아이셀 진 테라퓨틱스 엘엘씨 혈액 악성종양을 표적으로 하는 키메라 항원 수용체(car), 조성물 및 이의 용도
US10195272B2 (en) 2015-03-02 2019-02-05 The Nemours Foundation Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases
GB201504840D0 (en) * 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
AU2016243043B2 (en) * 2015-04-02 2021-12-09 Memorial Sloan Kettering Cancer Center TNFRSF14/ HVEM proteins and methods of use thereof
CA2981751A1 (en) 2015-04-08 2016-10-13 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
EP3283113A4 (en) * 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
GB201507115D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507119D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507111D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
EP4292664A3 (en) 2015-05-15 2024-06-12 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
DK3298033T4 (da) 2015-05-18 2023-10-02 Tcr2 Therapeutics Inc Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
WO2016210293A1 (en) 2015-06-25 2016-12-29 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
MX382532B (es) * 2015-08-05 2025-03-13 Cellabmed Inc Receptor de antigeno quimerico y celulas t en las cuales se expresa el receptor de antigeno quimerico.
WO2017024319A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
WO2017027392A1 (en) * 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
US10988542B2 (en) 2015-08-24 2021-04-27 Cellectis Chimeric antigen receptors with integrated controllable functions
EP4282979A3 (en) 2015-09-01 2024-02-28 The Regents of the University of California Modular polypeptide libraries and methods of making and using same
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
WO2017053889A2 (en) 2015-09-23 2017-03-30 Precision Immunotherapy, Inc. Flt3 directed car cells for immunotherapy
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
EP3377523A4 (en) * 2015-11-19 2019-06-19 The Regents of The University of California CONDITIONALLY REPRIMATABLE IMMUNOCELL RECEPTORS AND METHOD FOR USE THEREOF
US11001622B2 (en) 2015-11-19 2021-05-11 The Brigham And Women's Hospital, Inc. Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
WO2017091546A1 (en) * 2015-11-23 2017-06-01 Trustees Of Boston University Methods and compositions relating to chimeric antigen receptors
TWI765875B (zh) 2015-12-16 2022-06-01 美商磨石生物公司 新抗原辨識、製造及用途
EP3184548A1 (en) 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
EP3397755B1 (en) 2015-12-28 2024-11-06 Novartis AG Methods of making chimeric antigen receptor -expressing cells
SG11201804038VA (en) 2016-01-08 2018-06-28 Univ California Conditionally active heterodimeric polypeptides and methods of use thereof
NZ743983A (en) 2016-01-11 2025-08-29 Univ Leland Stanford Junior Chimeric proteins and methods of regulating gene expression
EA201891614A1 (ru) 2016-01-11 2019-02-28 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Химерные белки и способы иммунотерапии
CN105567640A (zh) * 2016-01-27 2016-05-11 苏州佰通生物科技有限公司 一种嵌合抗原受体脂肪干细胞及其制备方法
GB201602563D0 (en) * 2016-02-12 2016-03-30 Autolus Ltd Signalling system
GB201602571D0 (en) * 2016-02-12 2016-03-30 Autolus Ltd Signalling system
US10871490B2 (en) 2016-02-29 2020-12-22 Multenyi Biotec, gmbH Assay for detection of chimeric antigen receptor T cells
KR102584300B1 (ko) * 2016-03-29 2023-10-05 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
AU2017240233B2 (en) * 2016-03-31 2022-07-14 University Of Southern California A highly sensitive and specific luciferase based reporter assay for antigen detection
KR102397674B1 (ko) 2016-04-01 2022-05-18 카이트 파마 인코포레이티드 Bcma 결합 분자 및 그의 사용 방법
WO2017173410A1 (en) 2016-04-01 2017-10-05 Amgen Inc. Chimeric receptors to flt3 and methods of use thereof
SG11201808411RA (en) 2016-04-01 2018-10-30 Kite Pharma Inc Chimeric antigen and t cell receptors and methods of use
UA128781C2 (uk) 2016-04-01 2024-10-23 Кайт Фарма, Інк. Т-клітина, спосіб її отримання та застосування
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN109311963A (zh) 2016-04-14 2019-02-05 蓝鸟生物公司 救助嵌合抗原受体系统
AU2017250769B2 (en) 2016-04-15 2022-07-14 Memorial Sloan Kettering Cancer Center Transgenic T cell and chimeric antigen receptor T cell compositions and related methods
PL3455261T3 (pl) 2016-05-13 2022-12-12 Bioatla, Inc. Przeciwciała anty-ror2, fragmenty przeciwciał, ich immunokoniugaty oraz ich zastosowania
US20210177896A1 (en) 2016-06-02 2021-06-17 Novartis Ag Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
JP7114490B2 (ja) 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
US11384156B2 (en) 2016-07-25 2022-07-12 The Nemours Foundation Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
JP7109789B2 (ja) 2016-08-02 2022-08-01 ティーシーアール２ セラピューティクス インク． 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
CA3000514A1 (en) 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Cancer antigen targets and uses thereof
CN109789164B (zh) * 2016-08-30 2023-04-28 亘喜生物科技（上海）有限公司 具有gitr胞内结构域作为共刺激结构域的嵌合抗原受体
US20180064758A1 (en) * 2016-09-05 2018-03-08 Ucl Business Plc Chimeric antigen receptor
CN107793483B (zh) * 2016-09-06 2019-08-23 伍志强 嵌合抗原受体及其基因和重组表达载体、carmsln-nkt细胞及其制备方法和应用
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
US10683355B2 (en) 2016-09-16 2020-06-16 Kissei Pharmaceutical Co., Ltd. Genetically-modified cells and method for producing same
JP6887492B6 (ja) * 2016-10-04 2021-07-14 プレシジョン バイオサイエンシズ，インク． 遺伝子改変細胞で使用するための共刺激ドメイン
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
CN110225927B (zh) 2016-10-07 2024-01-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
BR112019007100A2 (pt) 2016-10-07 2019-06-25 Tcr2 Therapeutics Inc composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
EP4092049A1 (en) * 2016-10-20 2022-11-23 Celgene Corporation Cereblon-based heterodimerizable chimeric antigen receptors
US12227578B2 (en) 2016-11-11 2025-02-18 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through T cell action
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
CN107058315B (zh) * 2016-12-08 2019-11-08 上海优卡迪生物医药科技有限公司 敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用
EP3555296A4 (en) * 2016-12-13 2020-07-29 Seattle Children's Hospital (DBA Seattle Children's Research Institute) METHODS OF EXOGENOUS DRUG ACTIVATION OF CHEMICAL-INDUCED SIGNALING COMPLEXES EXPRESSED IN MODIFIED CELLS IN VITRO AND IN VIVO
US20200095301A1 (en) 2016-12-14 2020-03-26 The Board Of Trustees Of The Leland Stanford Junior University Il-13 superkine: immune cell targeting constructs and methods of use thereof
JP7382829B2 (ja) 2017-01-10 2023-11-17 ザ ジェネラル ホスピタル コーポレイション キメラ抗原受容体を発現するｔ細胞
CN107573419A (zh) * 2017-01-24 2018-01-12 深圳市体内生物医药科技有限公司 一种增强t细胞抗肿瘤活性的核酸分子
CN110612119B (zh) 2017-02-07 2024-10-29 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
WO2018148440A1 (en) * 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
EP3589646A4 (en) * 2017-03-03 2021-01-20 Obsidian Therapeutics, Inc. CD19 COMPOSITIONS AND PROCEDURES FOR IMMUNOTHERAPY
TW201837175A (zh) 2017-03-13 2018-10-16 美商凱特製藥公司 用於黑色素瘤之嵌合抗原受體及其用途
WO2018182511A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
AU2018246235B2 (en) 2017-03-27 2023-12-21 National University Of Singapore Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy
JOP20180027A1 (ar) 2017-03-28 2019-01-30 Cell Design Labs Inc بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها
JP7249287B2 (ja) 2017-03-31 2023-03-30 ザ・ボード・オブ・トラスティーズ・オブ・ザ・リーランド・スタンフォード・ジュニア・ユニバーシティ Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
WO2018183921A1 (en) 2017-04-01 2018-10-04 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
US20200071773A1 (en) 2017-04-12 2020-03-05 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
CA3060443A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
EP3622092A4 (en) 2017-05-11 2021-06-23 The Broad Institute, Inc. METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
EP3606950A1 (en) * 2017-05-12 2020-02-12 Cellectis Protease based switch chimeric antigen receptors for safer cell immunotherapy
WO2018211244A1 (en) * 2017-05-15 2018-11-22 Autolus Limited A cell comprising a chimeric antigen receptor (car)
CN107141356B (zh) * 2017-06-07 2020-03-13 胜武（北京）生物科技有限公司 一种光诱导二聚体型嵌合抗原受体
US11897953B2 (en) 2017-06-14 2024-02-13 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US11325957B2 (en) 2017-06-19 2022-05-10 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors
WO2018234862A1 (en) 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof
SG10202109108UA (en) 2017-06-21 2021-09-29 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars), compositions and methods thereof
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
CN107446937B (zh) * 2017-09-05 2020-12-25 深圳华云生物技术有限公司 嵌合抗原受体及其表达基因、光控调节的嵌合抗原受体修饰的t细胞及其应用
JP7382310B2 (ja) 2017-09-06 2023-11-16 カリフォルニア インスティチュート オブ テクノロジー シグナリング及び抗原提示の２機能性レセプター（ｓａｂｒ）
CN109504697A (zh) * 2017-09-15 2019-03-22 上海恒润达生生物科技有限公司 一种靶向人源化mesothelin的嵌合抗原受体的方法和用途
CA3070861A1 (en) * 2017-09-22 2019-03-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with enhanced nfkb signaling
CN109553686A (zh) * 2017-09-26 2019-04-02 南京安吉生物科技有限公司 一种新型可调控的双嵌合抗原受体t细胞及其构建方法和应用
GB201715918D0 (en) 2017-09-29 2017-11-15 Tc Biopharm Ltd Modified CAR-T
WO2019067677A1 (en) 2017-09-29 2019-04-04 Cell Design Labs, Inc. METHODS OF MANUFACTURING RECEPTORS OF ANTI-CD307E ANTI-BACTERIAL CHIMERIC ANTIGENS AND USES THEREFOR
WO2019070755A1 (en) 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
WO2019084055A1 (en) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
CN111566124A (zh) 2017-10-25 2020-08-21 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
WO2019094955A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
EP3710471A1 (en) 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
WO2019115818A2 (en) * 2017-12-14 2019-06-20 Celyad S.A. Pooling signaling and costimulatory domains in flexible car design
WO2019118895A1 (en) * 2017-12-14 2019-06-20 Bluebird Bio, Inc. Daric interleukin receptors
EP3502130A1 (en) 2017-12-20 2019-06-26 St. Anna Kinderkrebsforschung Ligand regulated protein-protein interaction system
CA3086032A1 (en) 2017-12-20 2019-06-27 St. Anna Kinderkrebsforschung Ligand regulated protein-protein interaction system
ES3037765T3 (en) 2017-12-22 2025-10-07 Fate Therapeutics Inc Enhanced immune effector cells and use thereof
WO2019126358A1 (en) * 2017-12-22 2019-06-27 Cell Design Labs, Inc. Single- and multi-chain chimeric antigen receptors
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
WO2019134950A1 (en) 2018-01-04 2019-07-11 Miltenyi Biotec Gmbh Chimeric antigen receptor specific for bdca2 antigen
CN120154716A (zh) 2018-01-22 2025-06-17 恩多塞特公司 Car t细胞的使用方法
CN108017717B (zh) * 2018-01-24 2019-08-16 首都医科大学宣武医院 一种用于体外高效定向扩增的嵌合抗原受体及其应用
CN111936518A (zh) 2018-02-06 2020-11-13 西雅图儿童医院（Dba西雅图儿童研究所） 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
CA3089287A1 (en) 2018-02-08 2019-08-15 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
US12258381B2 (en) 2018-02-09 2025-03-25 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
WO2019157496A1 (en) * 2018-02-12 2019-08-15 University Of Florida Researchfoundation, Inc. Fviii chimeric antigen receptor tregs for tolerance induction in hemophilia a
WO2019161271A1 (en) 2018-02-16 2019-08-22 Kite Pharma, Inc. Modified pluripotent stem cells and methods of making and use
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
TW202000229A (zh) 2018-02-23 2020-01-01 美商安德賽特公司 Car t細胞療法之順序方法
EP3759131A4 (en) 2018-02-27 2021-12-01 Gritstone bio, Inc. NEO-ANTIGEN IDENTIFICATION USING PAN-ALLEL MODELS
EP3759491A1 (en) * 2018-03-01 2021-01-06 H. Hoffnabb-La Roche Ag Specificity assay for novel target antigen binding moieties
CA3092794A1 (en) 2018-03-01 2019-09-06 University Of Kansas Techniques for generating cell-based therapeutics using recombinant t cell receptor genes
WO2019177986A1 (en) * 2018-03-12 2019-09-19 Nantkwest, Inc. Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
WO2019175209A1 (en) * 2018-03-14 2019-09-19 Medigene Immunotherapies Gmbh Inducible t cell receptors and uses thereof
CA3093020A1 (en) 2018-03-29 2019-10-03 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
WO2019193476A1 (en) 2018-04-02 2019-10-10 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
US20210023136A1 (en) * 2018-04-06 2021-01-28 The Regents Of The University Of California Trans-antigen targeting in heterogeneous cancers and methods of use thereof
EP3773633A4 (en) 2018-04-06 2022-01-26 The Regents of The University of California METHODS OF TREATMENT OF GLIOBLASTOMA
EP3773632A4 (en) 2018-04-06 2022-05-18 The Regents of The University of California Methods of treating egfrviii expressing glioblastomas
JP7479290B2 (ja) 2018-04-10 2024-05-08 アムジエン・インコーポレーテツド Ｄｌｌ３に対するキメラ受容体及びその使用方法
CN108410908B (zh) * 2018-04-12 2021-08-03 吉林大学 一种利用植物激素ga及小分子物质pac调节细胞通路的方法
WO2019197676A1 (en) * 2018-04-13 2019-10-17 Ludwig Institute For Cancer Research Ltd Heterodimeric inactivatable chimeric antigen receptors
WO2019203600A1 (ko) 2018-04-18 2019-10-24 앱클론(주) 스위치 분자 및 스위처블 키메라 항원 수용체
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
CN108715616A (zh) * 2018-04-27 2018-10-30 上海恒润达生生物科技有限公司 靶向人源化间皮素的嵌合抗原受体方法和用途
CA3091490A1 (en) 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Rapamycin resistant cells
WO2019210207A2 (en) * 2018-04-27 2019-10-31 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor t regulatory cells for the treatment of atherosclerosis
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
IL321548A (en) * 2018-05-22 2025-08-01 Immunitybio Inc Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
CA3102097A1 (en) 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior Unversity Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
CN110577604A (zh) * 2018-06-07 2019-12-17 亘喜生物科技（上海）有限公司 携带gitr共刺激信号靶向egfr的嵌合抗原受体t细胞
MX2020013443A (es) 2018-06-13 2021-02-26 Novartis Ag Receptores de antigeno quimerico de bcma y usos de los mismos.
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2019246563A1 (en) 2018-06-22 2019-12-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
CN110669138A (zh) * 2018-07-02 2020-01-10 中国药科大学 一种双嵌合抗原受体、t细胞及其构建方法与应用
EP3821012A4 (en) 2018-07-13 2022-04-20 The Regents of The University of California Retrotransposon-based delivery vehicle and methods of use thereof
CN118955734A (zh) 2018-07-18 2024-11-15 美国安进公司 针对steap1的嵌合受体及其使用方法
EP3833742A2 (en) 2018-08-09 2021-06-16 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
EP3837357A1 (en) 2018-08-13 2021-06-23 Aarhus Universitet Genetically altered lysm receptors with altered agonist specificity and affinity
US12486514B2 (en) 2018-08-29 2025-12-02 National University Of Singapore Method to specifically stimulate survival and expansion of genetically-modified immune cells
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
AU2019331496A1 (en) 2018-08-31 2021-03-18 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CN112823166B (zh) * 2018-09-07 2025-01-24 生物蛋白有限公司 用于修饰的t细胞的条件活性嵌合抗原受体
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
EP3632460A1 (en) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
EP3860642A1 (en) * 2018-10-05 2021-08-11 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
EP3632461A1 (en) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
CA3109747A1 (en) * 2018-10-05 2020-04-09 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
GB201816839D0 (en) * 2018-10-16 2018-11-28 Glaxosmithkline Ip Dev Ltd Novel control switch
WO2020117526A1 (en) 2018-12-02 2020-06-11 Fate Therapeutics, Inc. IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
WO2020117952A2 (en) 2018-12-05 2020-06-11 Genentech, Inc. Diagnostic methods and compositions for cancer immunotherapy
WO2020118305A1 (en) * 2018-12-07 2020-06-11 The Trustees Of Columbia University In The City Of New York Muc4 car-t cells for treating cancer
MX2021006968A (es) 2018-12-12 2021-10-13 Kite Pharma Inc Antígeno quimérico y receptores de las células t, y métodos de uso.
US12291560B2 (en) 2018-12-14 2025-05-06 Regeneron Pharmaceuticals, Inc. Dimerizing agent regulated immunoreceptor complexes
AU2019396553A1 (en) 2018-12-14 2021-06-24 Regeneron Pharmaceuticals, Inc. Dimerizing agent regulated immunoreceptor complexes
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
WO2020141106A1 (en) 2019-01-03 2020-07-09 Kemijski Institut Engineered externally regulated artificial transcription regulatory system based on engineered nfat
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
ES3051182T3 (en) 2019-01-23 2025-12-26 Miltenyi Biotec Bv & Co Kg A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
MX2021010441A (es) 2019-03-01 2021-09-21 Allogene Therapeutics Inc Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
CN118546959A (zh) * 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
US20220193137A1 (en) 2019-04-04 2022-06-23 Umc Utrecht Holding B.V. Modified immune receptor constructs
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
AU2020259449A1 (en) 2019-04-17 2021-12-09 Aadigen, Llc Peptides and nanoparticles for intracellular delivery of molecules
MY204280A (en) 2019-04-26 2024-08-21 Allogene Therapeutics Inc Rituximab-resistant chimeric antigen receptors and uses thereof
BR112021021349A2 (pt) 2019-04-26 2022-02-01 Allogene Therapeutics Inc Métodos de fabricação de células car t alogênicas
BR112021021075A2 (pt) 2019-05-01 2021-12-14 Editas Medicine Inc Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos
BR112021021200A2 (pt) 2019-05-01 2021-12-21 Juno Therapeutics Inc Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos
CN114127115A (zh) 2019-05-04 2022-03-01 印希比股份有限公司 结合CLEC12a的多肽及其用途
WO2020224605A1 (zh) * 2019-05-07 2020-11-12 亘喜生物科技（上海）有限公司 靶向bcma的工程化免疫细胞及其用途
JP7741732B2 (ja) 2019-05-07 2025-09-18 グレイセル・バイオテクノロジーズ（シャンハイ）カンパニー・リミテッド Ｂｃｍａを標的とする操作された免疫細胞及びその使用
SG11202111927QA (en) 2019-05-08 2021-11-29 2Seventy Bio Inc Cll-1 targeted immunotherapies
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
US20220226464A1 (en) 2019-05-28 2022-07-21 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
JP7606472B2 (ja) 2019-05-28 2024-12-25 ミルテニイ ビオテック ベー．ファー． ウント コー．カーゲー 遺伝子改変ｔ細胞の生成方法
KR20250095757A (ko) 2019-06-21 2025-06-26 카이트 파마 인코포레이티드 TGF-β 수용체 및 이의 사용 방법
WO2021016606A1 (en) * 2019-07-24 2021-01-28 Eureka Therapeutics, Inc. Chimeric antigen receptor t cells and uses thereof
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
US20220298501A1 (en) 2019-08-30 2022-09-22 The Broad Institute, Inc. Crispr-associated mu transposase systems
WO2021047804A1 (en) 2019-09-11 2021-03-18 Miltenyi Biotec B.V. & Co. KG In vitro method for transduction of t cells in the presence of malignant cells
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
MX2022003885A (es) * 2019-10-08 2022-07-13 Provincial Health Services Authority Receptores quimericos de citoquinas.
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
US20230053013A1 (en) * 2019-12-03 2023-02-16 University Of Massachusetts Compositions and methods for optogenetic immunotherapy
CN113087805A (zh) * 2019-12-31 2021-07-09 华东师范大学 一种共表达免疫调节分子的嵌合抗原受体t细胞的制备及其应用
CA3164666A1 (en) * 2020-01-13 2021-07-22 Kanya Lakshmi RAJANGAM Bcma-directed cellular immunotherapy compositions and methods
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
CA3165346A1 (en) 2020-01-23 2021-07-29 George Q. Daley Stroma-free t cell differentiation from human pluripotent stem cells
WO2021156277A1 (en) 2020-02-04 2021-08-12 Miltenyi Biotec B.V. & Co. KG Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
CN115427451A (zh) * 2020-02-14 2022-12-02 北京永泰瑞科生物科技有限公司 过表达从外部导入的细胞信号调节因子的免疫细胞及其用途
US20230111593A1 (en) 2020-02-14 2023-04-13 Novartis Ag Method of predicting response to chimeric antigen receptor therapy
EP4110377A2 (en) 2020-02-27 2023-01-04 Novartis AG Methods of making chimeric antigen receptor-expressing cells
MX2022010604A (es) 2020-02-27 2022-09-09 Novartis Ag Metodos de produccion de celulas que expresan receptores antigenicos quimericos.
WO2021183761A1 (en) * 2020-03-11 2021-09-16 The Trustees Of The University Of Pennsylvania Methods and composition for gene delivery using an engineered viral particle
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
AU2021256053A1 (en) 2020-04-17 2022-11-10 City Of Hope FLT3-targeted chimeric antigen receptor modified cells for treatment of FLT3-positive malignancies
EP3916388A1 (en) 2020-05-27 2021-12-01 Miltenyi Biotec B.V. & Co. KG Reagents for detection of chimeric antigen receptor cells
EP3915578A1 (en) 2020-05-28 2021-12-01 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor with a spacer comprising c2-set ig-like domains
EP4165171A4 (en) * 2020-06-12 2025-03-26 Nkarta, Inc. GENETICALLY MODIFIED NATURAL KILLER CELLS FOR CD70-DIRECTED CANCER IMMUNOTHERAPY
WO2021258016A1 (en) 2020-06-19 2021-12-23 Fate Therapeutics, Inc. Combining ipsc-derived effector cell types for immunotherapy use
KR20230042283A (ko) 2020-06-26 2023-03-28 주노 테라퓨틱스 게엠베하 재조합 수용체를 조건부로 발현하는 조작된 ｔ 세포, 관련된 폴리뉴클레오티드 및 방법
KR102859548B1 (ko) * 2020-08-20 2025-09-12 에이투 바이오쎄라퓨틱스, 인크. 메소텔린 양성 암을 치료하기 위한 조성물 및 방법
EP3964585A1 (en) 2020-09-03 2022-03-09 Miltenyi Biotec B.V. & Co. KG Cd62l specific lentiviral vector particle for targeted transduction of t cell subsets
WO2022049217A1 (en) 2020-09-04 2022-03-10 Miltenyi Biotec B.V. & Co. KG System for inducible expression of an adapter in immune cells
WO2022098638A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
JP7716473B2 (ja) 2020-11-04 2025-07-31 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
KR20230095113A (ko) 2020-11-04 2023-06-28 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체들과 항-cd79b 항체 약물 접합체들을 이용한 치료를 위한 투약
US20230405047A1 (en) 2020-11-09 2023-12-21 Miltenyi Biotec B.V. & Co. KG Methods and compositions for eliminating engineered immune cells
IL302700A (en) 2020-11-13 2023-07-01 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
EP4251742A4 (en) 2020-11-24 2025-01-08 Lyell Immunopharma, Inc. METHODS OF MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING REGENERATED T CELLS
WO2022140388A1 (en) 2020-12-21 2022-06-30 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
CA3209126A1 (en) * 2021-01-29 2022-08-04 Outpace Bio, Inc. Small molecule-regulated cell signaling expression system
US20240115608A1 (en) * 2021-02-10 2024-04-11 The Regents Of The University Of California Immune receptors with synthetic co-stimulatory domains
KR20230148837A (ko) 2021-02-25 2023-10-25 라이엘 이뮤노파마, 인크. Ror1 표적화 키메라 항원 수용체
GB202104030D0 (en) * 2021-03-23 2021-05-05 Autolus Ltd Signalling system
US20240180969A1 (en) * 2021-04-01 2024-06-06 A2 Biotherapeutics, Inc. Polypeptides targeting hla-a*11 and methods of use thereof
TW202310871A (zh) 2021-05-14 2023-03-16 美商建南德克公司 用莫蘇妥珠單抗及帕羅托珠單抗維多汀治療ｃｄ２０陽性增生性失調之方法
GB202108366D0 (en) 2021-06-11 2021-07-28 Quell Therapeutics Ltd Multichain chimeric antigen receptor
WO2023009989A1 (en) 2021-07-26 2023-02-02 Kite Pharma, Inc. Split chimeric antigen receptors and methods of use
WO2023044304A1 (en) * 2021-09-15 2023-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
EP4413031A1 (en) 2021-10-06 2024-08-14 Miltenyi Biotec B.V. & Co. KG Method for targeted gene insertion into immune cells
AU2022366987A1 (en) 2021-10-14 2024-05-16 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
WO2023062113A1 (en) 2021-10-15 2023-04-20 Miltenyi Biotec B.V. & Co. KG Method for the generation of genetically modified nk cells
WO2023130462A1 (zh) * 2022-01-10 2023-07-13 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的嵌合抗原受体及其用途
CN114736306B (zh) * 2022-03-01 2024-04-19 中国科学院深圳先进技术研究院 一种受化学调控的蛋白酶工具及其配套底物
WO2023187031A1 (en) 2022-04-01 2023-10-05 Miltenyi Biotec B.V. & Co. KG A system for drug-inducible expression of a polynucleotide
JP7707304B2 (ja) 2022-04-08 2025-07-14 フェイト セラピューティクス，インコーポレイティド 腫瘍標的化のためのキメラ抗原受容体
WO2023196994A1 (en) 2022-04-08 2023-10-12 Fate Therapeutics, Inc. Cells having solid tumor targeting backbone and use thereof
US20250295773A1 (en) 2022-05-10 2025-09-25 Miltenyi Biotec B.V. & Co. KG Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy
US20250313815A1 (en) * 2022-05-13 2025-10-09 Northwestern University Active loading of cargo entity into lipid bilayer particles using dimerization domains
WO2023222617A1 (en) 2022-05-16 2023-11-23 Miltenyi Biotec B.V. & Co. KG Endogenous signaling molecule activating chimeric antigen receptors and methods of generation thereof
WO2024050325A2 (en) * 2022-09-01 2024-03-07 Sri International Genetically engineered cd4 t-cells for in situ synthesis of proteins
IL319225A (en) 2022-09-15 2025-04-01 Novartis Ag Treatment of autoimmune disorders using antigen receptor chemotherapeutics
EP4342488A1 (en) 2022-09-26 2024-03-27 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor specific for folate receptor 1
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
WO2024078995A1 (en) 2022-10-15 2024-04-18 Miltenyi Biotec B.V. & Co. KG Transduction of gammadelta t cells with pseudotyped retroviral vectors
KR102834479B1 (ko) * 2022-11-04 2025-07-16 한국과학기술연구원 형광공명에너지전이 기반 car 활성 센싱용 바이오센서 및 그의 용도
TW202440623A (zh) 2022-11-28 2024-10-16 美商艾洛基因醫療公司 靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024158800A2 (en) * 2023-01-24 2024-08-02 Ginkgo Bioworks, Inc. Immune cell stimulatory sequences
WO2024182539A1 (en) 2023-02-28 2024-09-06 Lyell Immunopharma, Inc. Methods of culturing reprogrammed cells
EP4626447A1 (en) 2023-03-31 2025-10-08 AbelZeta Inc. Bispecific chimeric antigen receptors targeting cd20 and bcma
WO2024223847A1 (en) 2023-04-27 2024-10-31 Miltenyi Biotec B.V. & Co. KG Pseudotyped retroviral vector particle with anti-cd3 display
AU2024261890A1 (en) 2023-04-27 2025-10-09 Miltenyi Biotec B.V. & Co. KG Retroviral vector particle pseudotyped with envelope proteins of canine distemper virus
EP4470555A1 (en) 2023-05-31 2024-12-04 Miltenyi Biotec B.V. & Co. KG Anti-tag chimeric antigen receptors with specificity for mutated peptides derived from human fgfr2
EP4471067A1 (en) 2023-06-01 2024-12-04 Miltenyi Biotec B.V. & Co. KG A chemically inducible heterodimerizing system and a method for generation thereof
WO2025008108A1 (en) 2023-07-06 2025-01-09 Miltenyi Biotec B.V. & Co. KG Immune cell expressing chimeric antigen receptor and transgenic t cell receptor
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025078492A1 (en) 2023-10-13 2025-04-17 Miltenyi Biotec B.V. & Co. KG Cd3-targeted nipah-pseudotyped lentiviral vector particles
EP4545963A1 (en) 2023-10-26 2025-04-30 Miltenyi Biotec B.V. & Co. KG Method for selecting antigen recognizing moieties having specificity for a target structure
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
WO2025224123A1 (en) 2024-04-25 2025-10-30 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptors specific for fibroblast activation protein
WO2025252326A1 (en) 2024-06-06 2025-12-11 Miltenyi Biotec B.V. & Co. KG A human protein scaffold library based on the n-terminal domain of human fact complex subunit ssrp1
WO2025252325A1 (en) 2024-06-06 2025-12-11 Miltenyi Biotec B.V. & Co. KG A human protein scaffold library based on the pdz3 domain of the tight junction protein zo-1

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011119773A1 (en) 2010-03-23 2011-09-29 Roeth Jeremiah F Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2052928A1 (en) * 1990-10-15 1992-04-16 John J. Siekierka Genes encoding the human fk-506 binding protein and a.s. cerevisiae homolog, fkb1 and their expression
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
TW197439B (enExample) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
ES2197145T3 (es) 1991-08-20 2004-01-01 The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services Transferencia de genes mediada por adenovirus al gastrointestinal.
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1993010076A1 (en) 1991-11-22 1993-05-27 The University Of Mississippi Synthesis and optical resolution of the taxol side chain and related compounds
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
WO1993023555A1 (en) 1992-05-21 1993-11-25 The Penn State Research Foundation Cultured taxus tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
FI953812A0 (fi) 1993-02-12 1995-08-11 Univ Leland Stanford Junior Kohdistettujen geenien säädelty transkriptio ja muita biologisia toimintoja
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5310903A (en) 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
WO1995000655A1 (en) 1993-06-24 1995-01-05 Mc Master University Adenovirus vectors for gene therapy
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
ATE437232T1 (de) 1993-10-25 2009-08-15 Canji Inc Rekombinanter adenoviren-vektor und verfahren zur verwendung
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5527907A (en) 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5525610A (en) 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US20030036654A1 (en) 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US6150527A (en) 1994-08-18 2000-11-21 Ariad Pharmaceuticals, Inc. Synthetic multimerizing agents
US6133456A (en) 1994-08-18 2000-10-17 Ariad Gene Therapeutics, Inc. Synthetic multimerizing agents
CZ296981B6 (cs) 1994-12-09 2006-08-16 Imperial College Innovations Limited Zpusob pro identifikaci mikroorganizmu, zpusob identifikování genu, mikroorganizmus, vakcína a zpusob její prípravy, zpusob získání mutantního mikroorganizmu, zpusob prípravy farmaceutického prostredku, zpusob identifikace slouceniny a zpusob príprav
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
KR19990022651A (ko) 1995-06-07 1999-03-25 데이비드 엘. 버스테인 생물학적 사건에 대한 라파마이신 기재 조절방법
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US5821263A (en) 1996-08-26 1998-10-13 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
AU4966597A (en) 1996-11-19 1998-06-10 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
HUP0002521A3 (en) 1997-06-20 2002-04-29 Baker Norton Pharma Onium salts of paclitaxel, process for producing them and medicaments comprising the same
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
DE69729128T2 (de) 1997-10-08 2005-04-28 Bio Research Corporation Of Yokohama, Yokohama Taxoid-derivate und verfahren zu ihrer herstellung
CA2318402A1 (en) 1998-01-15 1999-07-22 Ariad Gene Therapeutics, Inc. Regulation of biological events using multimeric chimeric proteins
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
WO2001014387A1 (en) 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. 28-epirapalogs
GB9925854D0 (en) * 1999-11-01 1999-12-29 Celltech Therapeutics Ltd Biological products
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
US6916846B2 (en) 2000-05-12 2005-07-12 Merck & Co. Inc. Coumermycin analogs as chemical dimerizers of chimeric proteins
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
GB0105402D0 (en) 2001-03-05 2001-04-18 Inpharmatica Ltd Novel proteins
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
WO2003078575A2 (en) 2002-03-11 2003-09-25 The Johns Hopkins University Molecular switches and methods for making and using the same
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
WO2004073641A2 (en) 2003-02-18 2004-09-02 Kevin Slawin Induced activation in dendritic cells
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
US8236925B1 (en) 2005-08-26 2012-08-07 University Of Minnesota Protein nanorings
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
WO2011053825A2 (en) * 2009-10-30 2011-05-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment or prevention of mitochondrial diseases
AU2010343056A1 (en) 2009-12-29 2012-08-02 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
CA2796464C (en) 2010-04-16 2021-08-03 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
MX349622B (es) 2010-09-08 2017-08-07 Halozyme Inc Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
FR2968013A1 (fr) * 2010-11-29 2012-06-01 Cis Bio Int Methode de retention conditionnelle d'une proteine d'interet dans le reticulum endoplasmique
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
MX2013008376A (es) * 2011-01-18 2013-08-12 Univ Pennsylvania Composiciones y metodos para el tratamiento de cancer.
KR102437522B1 (ko) 2012-05-25 2022-08-26 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
WO2014039523A1 (en) 2012-09-04 2014-03-13 Cellectis Multi-chain chimeric antigen receptor and uses thereof
WO2014055657A1 (en) * 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
SI3613439T1 (sl) 2013-02-15 2021-11-30 The Regents Of The University Of California Himerni antigenski receptor in postopki njegove uporabe
JP6541639B2 (ja) 2013-03-14 2019-07-10 ベリカム ファーマシューティカルズ， インコーポレイテッド Ｔ細胞増殖をコントロールするための方法
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
JP6637415B2 (ja) * 2013-10-15 2020-01-29 ザ スクリプス リサーチ インスティテュート キメラ抗原受容体ｔ細胞スイッチおよびその使用
EP4420663A3 (en) 2013-12-20 2024-10-30 Novartis AG Regulatable chimeric antigen receptor
US10934346B2 (en) 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
WO2015142661A1 (en) * 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
RU2017115808A (ru) 2014-10-07 2018-11-13 Селлектис Способ модуляции активности car-индуцированных иммунных клеток
EP3377523A4 (en) 2015-11-19 2019-06-19 The Regents of The University of California CONDITIONALLY REPRIMATABLE IMMUNOCELL RECEPTORS AND METHOD FOR USE THEREOF
SG11201804038VA (en) 2016-01-08 2018-06-28 Univ California Conditionally active heterodimeric polypeptides and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011119773A1 (en) 2010-03-23 2011-09-29 Roeth Jeremiah F Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Current Opinion In Immunology Vol.21(2):215-223(2009. 4. 1.)
European Journal of Physiology, Vol.465(3):409-417(2013. 1. 9.)
Oncoimmunology Vol.1(9):1577-1583(2012. 12. 1.)

Also Published As

Publication number Publication date
IL240472B (en) 2020-02-27
LT3300745T (lt) 2019-12-10
US9821012B2 (en) 2017-11-21
CN110423282B (zh) 2023-09-08
MX369545B (es) 2019-11-12
AU2018201102A1 (en) 2018-03-08
ES2758227T9 (es) 2020-05-12
PL2956175T3 (pl) 2018-05-30
HK1218625A1 (zh) 2017-03-03
JP7014843B2 (ja) 2022-02-01
JP2022046809A (ja) 2022-03-23
EP2956175B1 (en) 2017-10-04
KR20150119134A (ko) 2015-10-23
KR102332790B1 (ko) 2021-12-01
IL272279A (en) 2020-02-27
US20180042963A1 (en) 2018-02-15
HUE036250T2 (hu) 2018-06-28
LT2956175T (lt) 2017-12-11
SI3613439T1 (sl) 2021-11-30
JP2020121982A (ja) 2020-08-13
NO2929995T3 (enExample) 2018-02-03
CA2901115A1 (en) 2014-08-21
EP3881868B1 (en) 2023-09-27
AU2019246785B2 (en) 2021-04-08
PT3613439T (pt) 2021-05-12
MX2019013498A (es) 2020-01-20
EP3881868A1 (en) 2021-09-22
US11478510B2 (en) 2022-10-25
EP4303232A2 (en) 2024-01-10
AU2014216130B2 (en) 2017-11-16
US20230051989A1 (en) 2023-02-16
AU2014216130A1 (en) 2015-08-27
EP4303232A3 (en) 2024-04-17
ES2868247T3 (es) 2021-10-21
US20170143765A1 (en) 2017-05-25
AU2021204054A1 (en) 2021-07-08
US20250136659A1 (en) 2025-05-01
US20150368342A1 (en) 2015-12-24
IL272279B1 (en) 2023-10-01
US10105391B2 (en) 2018-10-23
JP2016508518A (ja) 2016-03-22
PL3613439T3 (pl) 2021-11-22
PT3300745T (pt) 2019-11-27
WO2014127261A1 (en) 2014-08-21
EP2956175A1 (en) 2015-12-23
US12371466B2 (en) 2025-07-29
JP6450690B2 (ja) 2019-01-09
JP2023145542A (ja) 2023-10-11
EP3613439B1 (en) 2021-04-07
US20200237824A1 (en) 2020-07-30
CN110423282A (zh) 2019-11-08
BR112015019640A2 (pt) 2021-08-03
HRP20192123T1 (hr) 2020-02-21
AU2019246785A1 (en) 2019-10-31
MX2015010522A (es) 2016-06-23
JP2019068822A (ja) 2019-05-09
US9587020B2 (en) 2017-03-07
DK3300745T3 (da) 2019-11-04
IL240472A0 (en) 2015-09-24
PL3300745T3 (pl) 2020-03-31
ES2653487T3 (es) 2018-02-07
JP7317159B2 (ja) 2023-07-28
US20170340672A1 (en) 2017-11-30
KR20200083682A (ko) 2020-07-08
US20210196757A1 (en) 2021-07-01
AU2023204612B2 (en) 2025-04-24
JP6687712B2 (ja) 2020-04-28
DK2956175T3 (da) 2017-11-27
US20160185862A1 (en) 2016-06-30
AU2021204054B2 (en) 2023-04-20
AU2023204612A1 (en) 2023-08-03
US12161672B2 (en) 2024-12-10
KR20230022452A (ko) 2023-02-15
EP3881868C0 (en) 2023-09-27
KR20210147101A (ko) 2021-12-06
NZ750521A (en) 2021-03-26
HK1253407A1 (en) 2019-06-14
CY1122386T1 (el) 2021-01-27
EP3300745B1 (en) 2019-09-11
US10888581B2 (en) 2021-01-12
US20180085401A1 (en) 2018-03-29
ES2758227T3 (es) 2020-05-04
IL272279B2 (en) 2024-02-01
KR20190131152A (ko) 2019-11-25
EP3613439A1 (en) 2020-02-26
CN105142677A (zh) 2015-12-09
PT2956175T (pt) 2017-12-26
HUE047487T2 (hu) 2020-04-28
CN105142677B (zh) 2019-08-30
EP3300745B9 (en) 2020-04-15
IL305629A (en) 2023-11-01
US10632152B2 (en) 2020-04-28
JP7676476B2 (ja) 2025-05-14
EP2956175A4 (en) 2016-08-24
EP3300745A1 (en) 2018-04-04
SI3300745T1 (sl) 2020-01-31
NZ710925A (en) 2021-03-26
KR102813881B1 (ko) 2025-05-28
KR102064230B1 (ko) 2020-01-13

Similar Documents

Publication Publication Date Title
JP7676476B2 (ja) キメラ抗原受容体及びその使用方法
HK40106034A (en) Chimeric antigen receptor and methods of use thereof
HK40050006A (en) Chimeric antigen receptor and methods of use thereof
HK40020273A (en) Chimeric antigen receptor and methods of use thereof
HK40020273B (en) Chimeric antigen receptor and methods of use thereof
HK1253407B (en) Chimeric antigen receptor and methods of use thereof
HK40013763A (en) Chimeric antigen receptor and methods of use thereof
HK40013763B (zh) 嵌合抗原受体及其使用方法
HK1218625B (zh) 嵌合抗原受體及其使用方法

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20191118

Application number text: 1020157024731

Filing date: 20150909

PA0201 Request for examination
A302 Request for accelerated examination
PA0302 Request for accelerated examination

Patent event date: 20191119

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191224

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200407

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200702

Application number text: 1020157024731

Filing date: 20150909

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200703

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200703

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240620

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20250619

Start annual number: 6

End annual number: 6